Bayesian sample size calculations in phase II clinical trials using informative conjugate priors

被引:28
|
作者
Mayo, MS
Gajewski, BJ
机构
[1] Univ Kansas, Med Ctr, Sch Allied Hlth, Kansas City, KS 66160 USA
[2] Univ Kansas, Med Ctr, Sch Nursing, Kansas City, KS 66160 USA
[3] Univ Kansas, Med Ctr, Kansas Canc Inst,Med Stat & Res Design Unit, Dept Prevent Med & Publ Hlth, Kansas City, KS 66160 USA
来源
CONTROLLED CLINICAL TRIALS | 2004年 / 25卷 / 02期
关键词
beta; binomial; measure of location;
D O I
10.1016/j.cct.2003.11.006
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
A number of researchers have discussed phase 11 clinical trials from. a Bayesian perspective. A recent article by Tan and Machin focuses on sample size calculations, which they determine by specifying a diffuse prior distribution and then calculating a posterior probability that the true response will exceed a prespecified target. In this article, we extend these sample size calculations to include informative prior distributions using various strategies that allow researchers with both optimistic and pessimistic, priors direct involvement in the sample size decision making: We select the informative priors via multiple methods determined by the mean, median or mode of the conjugate prior. These cases can result in varying sample sizes. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:157 / 167
页数:11
相关论文
共 50 条